February 10, 2018 – Silenseed, a leading company in targeted treatments for solid tumors, announced that the company’ SLSG12D-P2 Phase 2 clinical trial in Locally Advanced Pancreatic Cancer (LAPC) is open, recruiting eligible patients in the Memorial Sloan Kettering Cancer Center in New York, USA. For more information see here